Patients
8.1 % of people 20–79
Diabetes (ages 20–79), Poland, 2024 (World Bank).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Poland Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$410.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $573.6 Mn | — | — |
| 2025 (base) | $607.4 Mn | +$33.8 Mn | — |
| 2026 (forecast) | $643.2 Mn | +$35.8 Mn | +5.9% |
| 2027 (forecast) | $681.2 Mn | +$38.0 Mn | +12.1% |
| 2028 (forecast) | $721.4 Mn | +$40.2 Mn | +18.8% |
| 2029 (forecast) | $763.9 Mn | +$42.6 Mn | +25.8% |
| 2030 (forecast) | $809.0 Mn | +$45.1 Mn | +33.2% |
| 2031 (forecast) | $856.7 Mn | +$47.7 Mn | +41.1% |
| 2032 (forecast) | $907.3 Mn | +$50.5 Mn | +49.4% |
| 2033 (forecast) | $960.8 Mn | +$53.5 Mn | +58.2% |
| 2034 (forecast) | $1.02 Bn | +$56.7 Mn | +67.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $607.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.02 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, route and end user (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all) |
| Regulator in Poland | URPLSource: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.
Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.
High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.
The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).[1] The National Health Fund (NFZ) pays for public care for insured people, and the Ministry of Health decides which medicines are reimbursed.[2] Diabetes (ages 20–79): 8.1% of people 20–79 in 2024, the latest World Bank figure for Poland.[3]
[1] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[2] National Health Fund (NFZ). Checked 19 Nov 2026.
[3] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 20 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Poland.
What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.
8.1 % of people 20–79
Diabetes (ages 20–79), Poland, 2024 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Diabetes (ages 20–79) (% of people 20–79). Retrieved 20 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.
From our blog
Poland · 2 shared keywords
Poland
Medical Devices · Poland
Medical Devices · Poland
Medical Devices · Global
Medical Devices · Global
Public Health · Global
Healthcare Services · Global